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PERCUTANEOUS ABSORPTION OF METHOTREXATE* 
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ABSTRACT 
The in vitro penetration of methotrexate (MTX) through human and hairless mouse skin 
was determined by two techn iques. One followed tritiated MTX by scintillation coun ting 
a nd the other followed cold MTX by dete rmining the inhibition of dihydrofolate reductase. 
Both techniques gave ample evidence for penetration of MTX through the skin of ha irless 
mice and man . 
There is no longer any doubt about the efficacy 
of methotrexate (MTX) in dermatology (1). Tox-
icity has limited its use in the treatment of pso-
riasis and other benign dermatoses. As the route 
of administration and other fa ctors appear to be 
relevant to the incid en ce of toxic effe cts, a 
number of different regimens have been suggested 
on theoretical grounds and are now being evalu-
ated. Ideally perhaps, topical application of the 
drug would reduce the incidence of side effects, 
a nd increase the speed of response. The primary 
biochemical target for the drug, dihydrofolate 
reductase, is present in the skin , and the level of 
the enzyme is known to be increased in psoriasis 
(2). However, clinical studies with topical MTX 
have been few and the results are conl1icting. Fry 
and McMinn discussed the earlier work and re-
ported so me clea ring of psoriasis wi t h the use of 
0.2% MTX in aqueous cream under polythene 
occlusion (3). Other studies, us ing 1% MTX in 
aqueous dimethylsulfoxide under polythene, pro-
duced local pain and ulceration, but no benefit (4). 
These authors showed that less than 0.55% of top-
ically applied MTX was excreted in the urine over 
72 hours, while most of the MTX remained in the 
stratum corneum . Van Scott and Reinertsen a lso 
reported the presence of MTX in the urine a fter 
topical app lication in psoriasis (5). We used two 
m ethods to ·study the penetrat ion of MTX 
through human skin in vitro. One was to apply 
t ritium -labeled MTX and assess penetration on 
the basis of recovery as measured by liquid sc in -
t illation counting. The other method was to assay 
t he recovered MTX on the basis of its ability to 
inhibit dihydrofolate reductase activi ty. 
METHODS AND MATERIALS 
Human leg skin was obtained from amputated limbs. 
Only skin a ppearing grossly normal was used, and 16- 20 
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separate specimens could be obtained from each leg. 
The subcutaneous fat was carefully removed with a 
scalpel after thawing, and the dermal surface was 
sponged with ethanol. Separate specimens were cut 
from each large piece and applied to the mouth of a 
glass cup with the dermal side facing inwards. The glass 
cup is open and continuous with a U-tube which is 
plugged with a glass stopper. This a llows filling of the 
cup with saline or buffer so that the dermis is fully 
ba thed (diagram in ref. 6). A plastic ring 1.5 em in di-
ameter is cemented to the epidermal side with Duco"' 
ce ment. Then 0.01 ml of labeled or cold MTX is appl ied 
to the epidermal surface, within the plastic ring. T he 
specimens are incubated in a humidi ty cha mber, at 30 o 
C wet bulb and 33°C dry bulb for 20 hours. Aliquots are 
then removed for scintillation counting or for biochem-
ical assay of MTX. 
The amount of MTX recovered from the saline or 
buffer on the dermal side is ca lculated and the per-
centage penetra tion can be easily determined, knowing 
the total amount app lied to the epiderma l surface. 
H ' labeled m ethotrexate. The 3' -5 '-T sodium salt 
(250 mCi/ mM, Amersham/Searle) was supplied by the 
genera ity of Lederle Laboratories. One millicurie was 
dissolved in 0.5 ml of dimethylacetamide (7). Four-fold 
dilut ions of this solution were made so that 0.01 ml ap-
plied to the skin contained 32, 8, 2, or 0.5 micrograms of 
MTX per 1.24 em ' · Standard precautions a nd correc-
tions were made for quenching. For each experiment, 
one large skin spec imen was divided in to 16 separate 
uni ts so that four penetration determinations could be 
made for each amount applied. The same proced ure was 
used to study penetration of H '-MTX through hairless 
mouse skin. The mice were 3- 4 months old, and the 
skin of the back of one mouse was used for each deter-
mination, using the sa me amounts of labeled MTX. 
With applications of 0.5 microgram H "-MTX per 1.24 
em ' (the lowest a mount of rad ioactivi ty applied in t hese 
experiments) we recovered activity 3- 6 times back -
ground . One ml aliquots were added to 12 ml of 
standard to luene based counting f1uid , and external 
standardi zation was used. Samples were counted with 
around 16% effi ciency. 
Cold methotrexate. Com mercia! MTX (Lederle La -
boratories) was made up to a 2.5% solut ion in 50 mM 
t ris-chloride with 1 M KCl, pH 7.2. The buffer was 
warmed to 40°C before use, and then cooled . The pene-
tration wells were fi lled with buffer (10 ml) a nd a ll a ir 
bubbles were removed. MTX concentrat ions of 0.5% 
and 2.5% were used, and 0.01 ml was applied to the epi-
derma l side of each well. A control group, using 0.03 ml 
of buffer a lone was always run in parallel. Light expo-
sure was kept to a minimum during these experiments. 
because of the known photo-decomposit ion of MTX. 
After 20 hours, a liquots were removed, checked for pH, 
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and then assayed. Dimethylacetamide (DMAC) was a lso 
used fo r maki ng up the MTX as ind icated. In these 
experi ments pure MTX powder was used , whi ch was a 
generous gift of Dr. Harriet K il t ie of Lederle Laborato-
ries. 
Preparation and purifi cation of dihydrofola te reduc-
tase. Dihydrofolate reduc tase was purified from Lacto-
bacillus casei stra in MTX/R as reported elsewhere (8). 
T he enzy me assay is based upon the decrease in optica l 
density at 340 nonometres, using a mul t iple sample 
absorbance record er, Gilford model 2000. The method of 
Mathews and Huenn ekens (9) was used except that the 
buffer was t ris-chloride, 50 mM, pH 7.5, and there was 
no mercaptoethanol present. All incubat ions and assays 
were carried out at 37° C, and under these condi t ions 
one uni t of enzy me activity will reduce one micromole 
of d ihydrofolate. In all cases, blanks were sub t rac ted 
from the resul ts . 
Biochemical assay of methotrexate. We used the prin -
ciple of Werkheiser et al. (10) based upon the sta nda rd 
assay procedure. T he stock L. casei dihydrofolate reduc-
tase was adjusted to 0. 1 units/ml and stabili zed with 
album in (0. 1 mg/ml) . T he standard assay conta ined in 
1.0 ml , 50 ll moles tris-chloride, pH 7.5, 0.01 unit en-
zyme, the sample, and the usua l amount of dihydrofo-
late. T he cuvette was pre- incubated for one minute at 
37° C, and the residua l activity assayed following the 
add ition of the standa rd a mount of NADP H. Metho-
t rexate was deemed to be absent fro m a solu t ion when 
the absorbance of the cont rol and sa mple cuvettes was 
similar. All assays were perfo rmed in t riplicate, and the 
average results compa red with a graph of the inhibi t ion 
of the enzyme produced by known concentrations of 
MTX. T he sensit ivity of the isotopic method is slightly 
greater than the assay procedure, but the coun ting 
method could include compounds derived from the 
MTX by degrada tion or other alte ration such tha t the 
enzyme might no longer be inhibited . T his could ex-
pla in the un iform presence of radioactivi ty in sa mples 
as compared to frequent absence of activity as measured 
by the biochem ical technique. 
RESULTS 
H • methotrexate. Table I shows the resul ts of 
t he assays using t ri tiated MTX in human and 
ha irless mouse ski n . T he amo un t penet rat in g 
vari ed grea tly between specimens, which is us u a l 
wi th this technique. However, it is clear t hat 
MTX ca n penetrate the skin of both ma n a n d 
mouse when a pplied topically. Wi th the vary ing 
amoun ts of MTX used (0.5- 32 t-tg/1.24 em "), t he r e 
were no signifi cant differences in percentage pe n -
etration. However, with hairless mouse skin there 
seemed to be a grea ter fraction absorbed with t h e 
lower amoun ts used. Thus, a t 32 t-tg/1.5 em" there 
was an average of 4.38% penetra tion compa re d 
with 16.3% a t 0.5 t-tg/1.24 em 2 • 
Cold methotrexate. Th e resul ts us ing huma n 
leg skin are summa ri zed in Table II. The solu . 
t ions were prepared as described above and each 
set of four resul ts refers to one group of adjacen t 
wells, each on a s mall port ion ta ken from a la rge 
spec imen . Indi vidua l va riations a re aga in ex. 
t remely wide a nd it is clear that the absorp t io n 
from weaker solut ions is relatively more effi cien t 
There is a suggestion that DMAC helps absorp~ 
t ion, as it reduced the number of zeros, but it did 
not change ove ra ll percentages penetratin g at 
each dose level. 
CO MMENT 
These resul ts show clearly that MTX can be 
absorbed through the dermis and epid ermis, but 
to a wid ely va riable extent, even between pieces 
of skin immediately adjoining one another. Some 
of this disc repancy may refl ect vari able adheren ce 
to the s tratum corneum (4). As the enzymic assay 
for MTX is a n opt ical one, the presence of oth er 
compounds wi th a n absorbance a t 340 na no-
metres, whether these are of na tural origin , d e-
ri ved from bacteria, or foreign material, could 
interfer with the assay. It is poss ible that some 
drug ta ken by the patien t could in!1uence t he 
assay as we ll (11), as we had no records for t he 
sources of the skin used. Tissue hea lth, bacterial 
action, the presence of drugs or their metaboli te 
could a ll influence the uptake of pteridines in t he 
TA BLE I 
Tri t ium -labeled methotrexate 
MTX applied %recovered from coch sumplc Avc ro gc recove red 
Man 0.5 llg 20 hours 2.74, 2.83, 3.4 3, 5.77 3.69% 
2.0 llg 20 hours 1.26, 1.54, 3.48, 4.19 2.74% 
8.0 llg 20 hours 0.92, 1.98, 3.50, 8.24 3.88% 
32.0 llg 20 hours 0.94, 2. 45, 2.74 , 6.95 3.27% 
Mouse 0.5 llg 20 hours 11.83, 12.46, 14 .36, 26.94 16.39% 
2.0 llg 20 hours 8.25, 8.57, 11.07, 14 .98 10.72% 
8.0 llg 20 hours 2.47, 2.81, 4.42, 6.00 3.92% 
4 hours• 0.62, 1.98, 5.39, 5.56 3.39% 
20 hours• 2.34, 5.61, 11 .02, 19.96 9.73% 
32.0 llg 20 hours 3.12, 3.60, 3.94 , 6.85 4.38% 
4 hours• 1.09, 2. 15, 2.36, 4.51 2.53% 
20 hours• 2.89, 7.38, 11.77, 19.02 9.52% 
• 4 hour and 20 hou r samples were from same spec imen. 
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Solvent 
Buffer 
Buffer 
DMAC 
TABLE II 
Penetrat£on of cold methotrexate 
All incubat ions were for 20 hours. 
MTX % MTX recovered from cnch 
applied sample 
0.1 mg 0, 0, 10.0, 24.0 
0, 0, 8.0, 12.0 
0, 0, 4.0, 8.0 
Above series combined : 
0.5 mg 0, 0, 0, 0 
0, 0, 4.8, 5.4 
0, 1.3, 1.3, 1.3 
Above series combined: 
0.1 mg 0, 4, 12.0, 24.0 
4.0, 4.0, 18.0, 20.0 
0, 0, 0, 12.0 
0, 0, 4.0, 8.0 
Above se ries co mbined : 
0.5 mg 0, 1.9, 2.7, 4.1 
1.0, 2.2, 5.0, 7.0 
0, 0, 0, 2.2 
0, 0, 1.0, 1.0 
Above series combined : 
Averog:c 
8.5% 
5.0% 
3.0% 
5.5% 
0 
2.55% 
0.95% 
1.1 5% 
10.0% 
11 .5% 
3.0% 
3.0% 
7. 15% 
2.15% 
3.8% 
0.55% 
0.50% 
1.75% 
skin , a nd perhaps a lso t he leve l of activity of di -
hydrofolate reductase. It is know n t hat fo late de-
pletion predis poses to MTX tox ic ity (12) , a nd in 
laboratory a nima ls M TX upta ke is increased by 
fo late d epletion (Newbold , P. C. H ., unpublished 
data). High levels of folate ca n reduce upta ke (13) , 
and t he rapidly growin g cells of t h e psoriatic 
populat ion may be protected from inhibitio n un t il 
systemic stores of folini c acid a re exha usted (14) . 
Leuke mi c ce ll s differ wid e ly in t he ir abili ty to 
t ra ns port a n t imeta boli tes, a nd t his fa vors t he 
selection of resista n t lines (15). The sam e phe -
nom eno n may be seen with the re lative ly imma-
ture cell s of psori at ic pla ques, a lt hough t hey may 
a lso ga in res istan ce by a lter ing t ra ns port as d o L 
1210 leukemia cell s (16). Rapid ly g rowing cells 
seem to be more vu lne rable to killin g by MTX 
(17) so psoriatic tissue should respond , as indeed 
it does after paren tera l ad ministrat ion . Liver a l-
te ra t ion of the dru g re ma ins a poss ibili ty, a l-
thou gh an unlike ly on e in view of t he kn own fact 
t hat th e bu lk o f a d ose is rapidly e liminated un -
changed in t he urin e (18). It has been shown t hat 
a numbe r of ions cons iderab ly inf1uen ce t h e ac-
tivity of dihydrofolate reducta e (19), so t hat pas -
sage of MTX through t he t issues, es pec ia lly if 
t h ey have been alte red by death a nd disease, may 
a lter the assay. N evertheless, our data show t hat 
activ ity inhibi tory to t he enzy me is recovered 
from t he derma l s ide of t he absorpt ion we lls . 
Recent work has shown that t here are non -s pe-
cific binding prote ins in a number of t issues, 
whi ch may be importan t in th e upta ke, storage 
a nd toxic ity of MTX (8). Some work in progress 
suggests t hat patients wit h psorias is have a dif-
fe ren t pattern, with fewer binding p roteins t ha n 
norm a l (20). T his cou ld explain t issue sens it ivi ty, 
a nd uptake patte rn s, as other evidence uggests 
that a n an ima l s pecies has one dihydrofolate re-
ductase in a ll o rga ns a nd tissues (21). We have 
confirmed satura bili ty of t he uptake mecha nis m 
as shown in other tissues (22) . This may expla in 
th e dis parity of t he results quoted a bove (3, 4). 
Eviden ce to date suggests t hat a t he rapeuti c ef-
fect mi gh t be seen in psoriatic lesions by t h e a p -
plication of dilute solutions of MTX under occlu -
s ion, protected from li gh t, and fo llowing t reat-
men t of t he lesions wi t h sodium az ide (23) . An-
other poss ibili ty, actively unde r investigation , is 
t hat so me othe r inhibi tor su ch as a quinazoline 
may be more effective (24). An t imetaboli tes can 
be of g reat va lue topically (14) and it may be only 
a matte r of t ime until psorias is also can be 
t reated in t hi s way. 
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